EUCTR2012-003488-23-BE进行中（未招募）1 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Fixed-dose Once-daily Oral Aripiprazole in Children and Adolescents with Tourette’s Disorder
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject is a male or female child or adolescent, 7-17 years of age (inclusive) at the time of signing the informed consent/assent.
- •2. The subject meets current DSM-IV-TR diagnostic criteria for Tourette’s Disorder, as confirmed by the K-SADS-PL, including the Diagnostic Supplement 5 (Substance Abuse and Other Diseases, ie, Tic Disorders).
- •3. The subject has a TTS = 20 on the YGTSS at Screening and Baseline (randomization).
- •4. The subject, a caregiver, and the investigator must all agree that the presenting tic symptoms cause impairment in the subject's normal routines, which include academic achievement, occupational functioning, social activities, and/or relationships.
- •5. Females of childbearing potential (defined by menarche and not having undergone surgical sterilization/hysterectomy) must have a negative pregnancy test, must be practicing acceptable double-barrier methods of contraception (or can confirm abstinence at each scheduled visit), and must not be pregnant or lactating.
- •6. Written informed consent must be obtained from a legally acceptable representative (eg, guardian or caregiver), in accordance with local law and the requirements of the trial center’s institutional review board (IRB) or independent ethics committee (IEC), prior to the initiation of any protocol-required procedures. In addition, the subject, as required by the trial center’s IRB/IEC, must provide informed assent at Screening and as such must be able to understand that he or she can withdraw from the trial at any time.
- •7. The subject and the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, as evaluated by the investigator.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 126
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. The subject presents with a clinical presentation and/or history that is consistent with another neurologic condition that may have accompanying abnormal movements.
- •These include, but are not limited to:
- •- Transient Tic disorder
- •- Huntington's disease
- •- Parkinson's disease
- •- Sydenham's chorea
- •- Wilson's disease
- •- Mental retardation
- •- Pervasive developmental disorder
- •- Traumatic brain injury
- •- Restless Legs Syndrome
- •2. The subject has a history of schizophrenia, bipolar disorder, or other psychotic disorder.
- •3. Subjects who receive psychostimulants for the treatment of ADD/ADHD and who have developed and/or had exacerbations of the tic disorder after the initiation of stimulant treatment (Note that subjects with ADD/ADHD who are treated with psychostimulants and have not developed new tics or a worsening of their current tics can be included if all other enrollment obligations are met).
- •4. The subject currently meets DSM-IV-TR criteria for a primary mood disorder.
- •5. The subject has severe obsessive-compulsive disease (OCD), as evidenced by a Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) score > 16.
- •6. The subject has taken aripiprazole within 1 month (30 days) of the Screening visit.
- •7. Subjects who received any investigational agent in a clinical trial within 30 days prior to Screening; or who were previously enrolled in Studies 31-10-272, 31-10-273, or 31-10-274; or who were randomized into a clinical trial with once-daily aripiprazole at any time.
- •8. The subject has a history of neuroleptic malignant syndrome.
- •9. Sexually active males who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 90 days following the last dose of study drug, or sexually active females of childbearing potential who will not commit to utilizing 2 of the approved birth control methods or who will not remain abstinent during the trial and for 30 days following the last dose of study drug. Abstinence will be permitted if it is confirmed and documented at every trial visit. If employing birth control, 2 of the following precautions must be used: vasectomy, tubal ligation, vaginal diaphragm, intrauterine device, birth control pill, birth control depot injections, implant, condom or sponge with spermicide.
- •10. Females who are breast-feeding and/or who have a positive serum pregnancy test result prior to receiving trial drug.
- •11. The subject represents a significant risk of committing suicide based on history (suicide attempt in past 1 year), routine psychiatric status examination, investigator’s judgment, or who have an answer of yes” on any question other than 1-3 (current or over the last 30 days) on the Baseline/Screening version of the Columbia-Suicide Severity Rating Scale (C-SSRS).
- •12. Body weight is lower than 16 kg.
- •13. Subjects who have taken neuroleptic or antiparkinson drugs less than 14 days prior to randomization.
- •14. Subjects requiring cognitive-behavioral therapy (CBT) for
- •Tourette’s Disorder during the trial period. CBT for other nonexclusionary disorders must remain consistent throughout the trial.
- •15. The subject has met DSM-IV-TR criteria for any significant psychoactive substance use disorder (abuse, dependence, and/or withdrawal) within the past 3 months.
- •16. A positive drug screen for cocaine, alcohol, or other drugs
- •of abuse (excluding caffeine, nicotine, or prescribed psychostimulants for ADD/ADHD). Investigators
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Subcutaneously in Subjects with Active Rheumatoid Arthritis and Previously Treated with Biologic Anti-TNFalfa Agent(s) - NAActive rheumatoid arthritis (RA)EUCTR2005-001742-16-NLCentocor B.V.420
招募中
不适用
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to evaluate the efficacy and safety of ginkgo biloba leaf ex. inj. in Salvage treatment for Sudden Deafness PatientsDiseases of the ear and mastoid processKCT0003292Asan Medical Center68
进行中（未招募）
不适用
A clinical trial to test the safety and effectiveness of aripiprazole against placebo in children and adolescents with Tourette’s DisorderEUCTR2012-003488-23-HUOtsuka Pharmaceutical Development & Commercialization, Inc.67
进行中（未招募）
1 期
A Study to Investigate safety and how well ABBV-323 works and how safe it is in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapylcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2018-000930-37-ESAbbVie Deutschland GmbH & Co. KG60
进行中（未招募）
不适用
Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) In The Treatment Of Children And Adolescent Outpatients With Major Depressive DisorderEUCTR2008-001875-32-Outside-EU/EEAPfizer Inc.363